SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCJuly 23, 2026

Zidesamtinib approved in the US for previously treated ROS1-positive NSCLC

The US Food and Drug Administration has approved zidesamtinib, sold under the brand name Jideytro, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have previously received a ROS1 kinase inhibitor. GSK announced the approval on 22 July, ahead of the agency's original target action date of 18 September 2026 and following Breakthrough Therapy and Orphan Drug designations. It is the company's first approved medicine in lung cancer, and reached GSK through its acquisition of Nuvalent, Inc., which the company announced as complete on 15 July.
Share
Zidesamtinib approved in the US for previously treated ROS1-positive NSCLC

In brief

  • The FDA has approved zidesamtinib, sold under the brand name Jideytro, for adults with locally advanced or metastatic ROS1-positive NSCLC who have already received a ROS1 kinase inhibitor. The decision came ahead of the original 18 September target action date.
  • Approval rests on 117 previously treated patients in the single-arm ARROS-1 trial. GSK reported an objective response rate of 44% (95% CI 34–53), with duration of response rates of 82% at six months and 69% at 12 months.
  • No survival data was released. GSK gave no progression-free or overall survival figures, no median duration of response, and no follow-up time.
  • GSK stated that responses occurred in patients with brain metastases and in patients with ROS1 resistance mutations, without separate figures for either group.
  • The adverse reactions reported in at least 15% of a pooled safety population of 446 patients included oedema, peripheral neuropathy, constipation, fatigue and dyspnoea.

Read the full announcement from GSK →

Study at a glance

  • Source trial: ARROS-1, phase I/II, single-arm, in advanced ROS1-positive NSCLC and other ROS1-positive solid tumours
  • Geography: multinational, with registered sites in 14 countries across North America, Europe and Asia-Pacific
  • Approval population: 117 patients with ROS1-positive NSCLC previously treated with a ROS1 inhibitor
  • Reported efficacy: objective response rate 44% (95% CI 34–53); duration of response rates 82% at six months, 69% at 12 months
  • Safety population: 446 patients (pooled)
  • Status: listed as recruiting, with an estimated enrolment of 359 participants (registry record last verified 2025)
  • Trial registration: ClinicalTrials.gov NCT05118789

A 44% response rate after a prior ROS1 inhibitor

ARROS-1 enrols patients with advanced ROS1-positive NSCLC and other ROS1-positive solid tumours. The approval rests on the 117 of them with NSCLC who had already been treated with a ROS1 inhibitor. In that population GSK reported an objective response rate of 44%, with a 95% confidence interval of 34% to 53%. Duration of response rates were 82% at six months and 69% at 12 months.

GSK stated that zidesamtinib continues to be studied in ARROS-1, including in first-line treatment for patients who have not previously received a ROS1 inhibitor. The registry still lists the trial as recruiting, with an estimated enrolment of 359 participants, on a record last verified in 2025.

Responses in the brain and against resistance mutations, but no figures for either

GSK noted that NSCLC often spreads to the central nervous system. The company stated that the responses seen in ARROS-1 included patients with brain metastases and patients with ROS1 resistance mutations, and described zidesamtinib as designed to combine target selectivity, broad coverage of ROS1 resistance mutations and blood-brain barrier penetration. Response rates specific to either group were not given in the announcement.

Alexander Drilon, an ARROS-1 investigator and Chief of the Early Development Service at Memorial Sloan Kettering Cancer Center, set the result against those problems. GSK disclosed in the same announcement that he has served as a consultant to Nuvalent and has received expense reimbursements from the company:

“Despite advances in treatment, resistance mutations, disease progression in the brain and treatment-related adverse events continue to create challenges for patients. The responses observed in ARROS-1, including in heavily pre-treated patients, represent meaningful progress for people living with this disease.”Alexander Drilon, MD, ARROS-1 trial investigator and Chief of the Early Development Service, Memorial Sloan Kettering Cancer Center

Oedema and peripheral neuropathy among the reactions reported in at least 15%

In a pooled safety population of 446 patients, GSK stated that the adverse reactions occurring in at least 15% included oedema, peripheral neuropathy, constipation, fatigue and dyspnoea, and did not present the list as exhaustive. The announcement gave no severity grading, no discontinuation rates and no dose-modification rates. GSK stated that the US prescribing information would be published on the manufacturer’s site.

The Nuvalent programmes behind GSK’s first lung cancer medicine

Zidesamtinib reached GSK through the Nuvalent acquisition, announced as complete a week before the approval. Two further Nuvalent candidates are named in the announcement: neladalkib (NVL-655) for ALK-altered NSCLC, under FDA review with a target decision date of 27 November 2026, and NVL-330, an investigational treatment for HER2-altered NSCLC. GSK is separately developing risvutatug rezetecan, a B7-H3-targeted antibody-drug conjugate licensed from Hansoh Pharma, which reported positive phase III results in relapsed small-cell lung cancer in a Chinese patient population earlier in July.

GSK put the annual worldwide incidence of ROS1-positive NSCLC at approximately 50,000, and described the patients as often non-smokers in their 40s and 50s who may remain on treatment for several years.

Sources

  1. GSK. Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer (2026-07-22). gsk.com

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard